From Morganton, North Carolina, USA:
Two weeks ago, my doctor prescribed prednisone for a sudden bout of hives, approximately seven days into this treatment, my blood pressure became very high, and I had to be taken off of the prednisone very quickly. Almost immediately I became dizzy and shaky, and generally felt terrible. Then, within a few days, I developed a rash on my arms, legs and back, and chest area which became hard to deal with.
I went to the doctor to talk about the rash, but he wanted to talk about my blood work done about three days after I discontinued the prednisone noting that my blood sugar was 149 mg/dl [mmol/L]. Two months previously, it was 111 mg/dl [mmol/L]. I take blood pressure medications and Pravachol, but I have never had any problems with my blood sugar.
Did the prednisone cause this rise in my blood sugar? Is it reversible? I have not been able to see the doctor since I had a two-hour glucose test done this week to get any answers from him, but it was up again when they did this. I am starting to get very concerned about this, and need some advice.
I would suggest you cannot make the diagnosis of typeá 2 diabetes in the presence of recent steroid therapy. However, individuals at increased risk for type 2 diabetes have their sugars rise with prednisone.
I would use the time with your physician to discuss ways to decrease your risk of developing diabetes.
Original posting 10 Feb 2002
Posted to Diagnosis and Symptoms
Last Updated: Tuesday April 06, 2010 15:09:30
This Internet site provides information of a general nature and is designed for educational purposes only. If you have any concerns about your own health or the health of your child, you should always consult with a physician or other health care professional.
This site is published by T-1 Today, Inc. (d/b/a Children with Diabetes), a 501c3 not-for-profit organization, which is responsible for its contents. Our mission is to provide education and support to families living with type 1 diabetes.
© Children with Diabetes, Inc. 1995-2017. Comments and Feedback.